Bardoxolone methyl oral capsule + Placebo oral capsule
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Autosomal Dominant Polycystic Kidney
Conditions
Autosomal Dominant Polycystic Kidney, ADPKD
Trial Timeline
May 29, 2019 → Aug 8, 2023
NCT ID
NCT03918447About Bardoxolone methyl oral capsule + Placebo oral capsule
Bardoxolone methyl oral capsule + Placebo oral capsule is a phase 3 stage product being developed by Biogen for Autosomal Dominant Polycystic Kidney. The current trial status is terminated. This product is registered under clinical trial identifier NCT03918447. Target conditions include Autosomal Dominant Polycystic Kidney, ADPKD.
What happened to similar drugs?
1 of 4 similar drugs in Autosomal Dominant Polycystic Kidney were approved
Approved (1) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
17
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04702997 | Phase 2 | Completed |
| NCT03918447 | Phase 3 | Terminated |
Competing Products
19 competing products in Autosomal Dominant Polycystic Kidney
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ABBV-CLS-628 + Placebo | AbbVie | Phase 2 | 42 |
| AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part B | AstraZeneca | Phase 1 | 36 |
| Placebo + Everolimus | Novartis | Approved | 43 |
| Octreotide + Placebo | Novartis | Phase 2/3 | 38 |
| Everolimus + Calcineurin inhibitors maintenance | Novartis | Phase 3 | 40 |
| Bosutinib + Bosutinib + Placebo | Pfizer | Phase 2 | 35 |
| VX-407 | Vertex Pharmaceuticals | Phase 2 | 42 |
| VX-407 + LNG/EE + NGM/EE + NET/EE + DRSP/EE | Vertex Pharmaceuticals | Phase 1 | 33 |
| VX-407 + Placebo + Midazolam + VX-407 | Vertex Pharmaceuticals | Phase 1 | 29 |
| VX-407 + Placebo | Vertex Pharmaceuticals | Phase 1 | 33 |
| Tesevatinib | Sanofi | Phase 1/2 | 32 |
| Tesevatinib + Placebo | Sanofi | Phase 2 | 35 |
| Venglustat + Placebo | Sanofi | Phase 2/3 | 30 |
| Lanreotide + saline | Ipsen | Phase 3 | 37 |
| KB105 | Krystal Biotech | Phase 2 | 28 |
| KB105 | Krystal Biotech | Phase 1/2 | 25 |
| Lixivaptan + Placebo | Centessa Pharmaceuticals | Phase 3 | 29 |
| GLPG2737 + Placebo | Galapagos | Phase 2 | 21 |
| QR-1123 | ProQR | Phase 1/2 | 26 |